Suxia Luo
Impact in
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Immunology top 5%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
Papers in
- Oncology 29
- Cancer Immunotherapy and Biomarkers 13
- HER2/EGFR in Cancer Research 6
-
- Gastric Cancer Management and Outcomes 10
- Ferroptosis and cancer prognosis 4
- Co-authors
- Ming Yi (16 shared papers)Kongming Wu (16 shared papers)Linping Xu (4 shared papers)Shuang Qin (3 shared papers)Mengke Niu (7 shared papers)Shengnan Yu (1 shared paper)Anping Li (6 shared papers)Bing Dong (6 shared papers)
- Journals
- Annals of Translational Medicine (7 papers)Journal of Hematology & Oncology (5 papers)Annals of Oncology (5 papers)Experimental Hematology and Oncology (4 papers)Medicine (2 papers)
- Partner nations
- ChinaUnited StatesJapan
In The Last Decade
Suxia Luo
83 papers receiving 4.2k citations
Suxia Luo's Hit Papers
Peers
Comparison fields: 5 of 110
- Oncology 1.9k
- Immunology 946
- Cancer Research 623
- Pulmonary and Respiratory Medicine 732
- Molecular Biology 1.1k
Countries citing papers authored by Suxia Luo
This map shows the geographic impact of Suxia Luo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suxia Luo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suxia Luo more than expected).
Fields of papers citing papers by Suxia Luo
This network shows the impact of papers produced by Suxia Luo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suxia Luo. The network helps show where Suxia Luo may publish in the future.
Co-authors
The 25 scholars most cited alongside Suxia Luo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 85 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4 Hit paper breakdown → | 2019 | 937 |
| 2 | Regulation of PD-L1 expression in the tumor microenvironment Hit paper breakdown → | 2021 | 496 |
| 3 | Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial Hit paper breakdown → | 2023 | 435 |
| 4 | The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1 Hit paper breakdown → | 2021 | 180 |
| 5 | 2020 | 178 | |
| 6 | 2021 | 160 | |
| 7 | 2020 | 150 | |
| 8 | 2021 | 122 | |
| 9 | 2019 | 117 | |
| 10 | 2021 | 99 | |
| 11 | 2019 | 96 | |
| 12 | 2021 | 93 | |
| 13 | 2020 | 88 | |
| 14 | 2018 | 86 | |
| 15 | 2014 | 83 | |
| 16 | 2021 | 80 | |
| 17 | 2021 | 80 | |
| 18 | 2022 | 52 | |
| 19 | 2022 | 46 | |
| 20 | 2020 | 43 |
About Suxia Luo
Suxia Luo is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Surgery and Immunology, having authored 85 papers that have together received 4.2k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (13 papers), Gastric Cancer Management and Outcomes (10 papers), HER2/EGFR in Cancer Research (6 papers), Esophageal Cancer Research and Treatment (5 papers), MicroRNA in disease regulation (5 papers), Immune cells in cancer (4 papers), Immune Cell Function and Interaction (4 papers) and Ferroptosis and cancer prognosis (4 papers). The work is most often cited by research in Oncology (1.9k citations), Immunology (946 citations), Cancer Research (623 citations), Pulmonary and Respiratory Medicine (732 citations) and Molecular Biology (1.1k citations). Suxia Luo has collaborated with scholars based in China, United States and Japan. Frequent co-authors include Ming Yi, Kongming Wu, Linping Xu, Shuang Qin, Mengke Niu, Shengnan Yu, Anping Li, Bing Dong, Qian Chu and Ying Jiao. Their work appears in journals such as Annals of Translational Medicine, Journal of Hematology & Oncology, Annals of Oncology, Experimental Hematology and Oncology and Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.